Trial
NCT06351332
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Filipa Lynce, MD
Collaborators
Merck Sharp & Dohme LLC; Zentalis Pharmaceuticals
Condition
Breast Cancer
Intervention
Azenosertib
Why stopped
Zentalis terminated contract due to concern for toxicity safety from previously reported serious adverse events. This study had been designed as a Phase I / Phase II study, but never reached Phase II.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-04